Some stocks and exchange traded funds cobble together a few months, maybe a year or two of solid gains before falling off. Rare are the investments that can deliver staggering returns over multiple years or even a decade.

The PowerShares Dynamic Pharmaceuticals Portfolio (NYSEArca: PJP) has done just that. PJP is a departure from the traditional market capitalization-weighted health care ETF in that its underlying index evaluates companies for inclusion based on “price momentum, earnings momentum, quality, management action, and value,” according to PowerShares. [A Fabulous Pharma ETF]

“PJP tracks an industry with seemingly endless demand from an aging population looking to live forever. What gave it the edge over its biotech peers is that it is concentrated in only 30 companies. ETFs with such a small number of holdings tend to do really well—or really poorly,” reports Eric Balchunas for Bloomberg.

As Bloomberg notes, PJP has returned a staggering 420% over the past decade. The ETF is again among this year’s top-performing sector funds.

However, if there is one thing PJP has recently become known for, aside from its stellar returns, it is being front-and-center in the pharmaceuticals industry consolidation. That theme, which has become increasingly prominent this year, has shined added light on the the $2.15 billion PJP, an ETF that recently celebrated its tenth anniversary. [Pharma ETFs Like Mylan-for-Perrigo News]

Showing Page 1 of 2